09-12-2021 | Non-small-cell lung cancer | Video
Speakers: Stephen Liu, Melina Marmarelis and Vivek Subbiah
Stephen Liu leads Melina Marmarelis and Vivek Subbiah in a discussion on the care of patients with RET fusion-positive NSCLC in light of the ARROW trial of pralsetinib.
Dr. Stephen Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University.
Browse contributions
Vivek Subbiah, MD, is an associate professor in the Investigational Cancer Therapeutics department (a Phase 1 program). He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division, at The University of Texas MD Anderson Cancer Center.
Browse contributions
Melina Marmarelis, MD, MSCE, is an assistant professor at the University of Pennsylvania and the Medical Director of the Penn Medicine Mesothelioma and Pleural Disease Program.
Full biography
Trial investigator on the ARROW study.
Trial investigator on the ARROW study.
Consulting/Honoraria: Boehringer Ingelheim, Novocure, AstraZeneca, Janssen, Takeda, Blueprint Pharmaceuticals, Bristol Myers Squibb, Ikena.
Research: Eli Lilly, Trizell, Merck, AstraZeneca.
Stock: Gilead, Merck, Portola pharmaceuticals, Bluebird Biosciences, Novartis, janssen, Pfizer.
Other: Novartis (medical writing support).
Adapted from Trends Cancer 2021; doi: 10.1016/j.trecan.2021.07.003
Adapted from 2021 ASCO Annual Meeting; doi: 10.1200/JCO.2021.39.15_suppl.9004
This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.